search
Back to results

Cervical Preparation Before Dilation and Evacuation

Primary Purpose

Abortion, Induced

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Mifepristone
misoprostol
Osmotic dilators
placebo
placebo
Sponsored by
Planned Parenthood League of Massachusetts
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abortion, Induced focused on measuring abortion, induced

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • 18 years and older
  • Able to give informed consent
  • Medically eligible for outpatient second trimester pregnancy termination at the clinical site
  • English-speaking or Spanish-speaking at sites with ability to obtain informed consent in Spanish

Exclusion Criteria:

  • Active bleeding (>1 pad/hour) or hemodynamically unstable at enrollment
  • Signs of chorioamnionitis or clinical infection at enrollment
  • Signs of spontaneous labor or cervical insufficiency at enrollment
  • Spontaneous intrauterine fetal demise
  • Patient incarcerated
  • Allergy to mifepristone or misoprostol
  • Chronic steroid use or adrenal insufficiency
  • Porphyria
  • Inflammatory bowel disease requiring treatment

Sites / Locations

  • San Francisco General Hospital
  • Family Planning Associates
  • Brigham and Women's Hospital
  • Boston Medical Center
  • Planned Parenthood of New York City
  • Lovejoy Surgical Center
  • Magee Women's Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Active Comparator

Active Comparator

Arm Label

Osmotic dilators + placebo (vit c) + placebo (vit B12)

Osmotic dilators + placebo (vit c) + misoprostol

Osmotic dilators + mifepristone + placebo (vit B12)

Arm Description

Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.

Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.

Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.

Outcomes

Primary Outcome Measures

Operative Time
The duration of the D&E procedure was measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D&E

Secondary Outcome Measures

Initial Cervical Dilation
Measured at the time of procedure (immediately before the start of D&E)
Ability to Complete the D&E on the First Attempt
Assessed on day of procedure and following day. If the procedure was unable to be completed as planned and the subject had to leave the procedure room and return for another attempt either at a time later the same day or the next day.
Need for Mechanical Dilation
Assessed on Day of procedure. Assessed immediately after completion of D&E
Ease of Mechanical Dilation
Number of participants for whom, if additional mechanical dilation was required, it was difficult or very difficult. Assessed on day of procedure. Assessed after completion of D&E
Complications From Procedure
Patient having any complication, including hospitalizations transfusions additional unplanned procedures
Chills (Any) After Day 2 Medication Administration
chills (any) after Day 2 medication administration
Patient Satisfaction With Cervical Prep
Patients who were very satisfied or satisfied with cervical preparation. Assessed on Day of procedure. Assessed after completion of D&E procedure and just prior to discharge home.
Physician Satisfaction With Cervical Preparation
Participants for whom the operating physician reported being satisfied or very satisfied with the cervical preparation. Assessed on Day of procedure. Assessed after completion of D&E procedure.

Full Information

First Posted
December 12, 2012
Last Updated
January 27, 2016
Sponsor
Planned Parenthood League of Massachusetts
Collaborators
Society of Family Planning
search

1. Study Identification

Unique Protocol Identification Number
NCT01751087
Brief Title
Cervical Preparation Before Dilation and Evacuation
Official Title
Cervical Preparation Before Dilation and Evacuation in the Second Trimester: A Multicenter Randomized Trial Comparing Osmotic Dilators Alone to Dilators Plus Adjunctive Misoprostol or Adjunctive Mifepristone.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Planned Parenthood League of Massachusetts
Collaborators
Society of Family Planning

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research study is to compare three different ways of opening a woman's cervix before her second-trimester surgical abortion. Osmotic dilators: small rods that, when inserted into the cervix, gently expand to open the cervix Osmotic dilators plus mifepristone, a medicine that is swallowed Osmotic dilators plus misoprostol, a medicine that is placed between the cheek and gum Hypotheses: adding buccal misoprostol 3 hours preoperatively will significantly improve dilation compared to laminaria alone, making procedures faster, easier and safer. adding oral mifepristone at the time of laminaria placement will confer a similar benefit. the efficacy of adjunctive misoprostol and mifepristone will be influenced by gestational age, with women later in gestation having increased efficacy from these agents. significantly more patients who receive adjunctive misoprostol or mifepristone will have adequate initial dilation, fewer will require manual dilation or additional cervical preparation and there will be fewer complications in these arms, although complication rates will be low and we will only be able to detect relatively large differences. patients will prefer to have the procedure done as quickly as possible with as little discomfort as possible, that cervical ripening with adjunctive misoprostol will be associated with more cramping than osmotic dilators alone and that mifepristone will be well tolerated and may not cause more cramping or other side effects than osmotic dilators alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abortion, Induced
Keywords
abortion, induced

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Osmotic dilators + placebo (vit c) + placebo (vit B12)
Arm Type
Other
Arm Description
Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Arm Title
Osmotic dilators + placebo (vit c) + misoprostol
Arm Type
Active Comparator
Arm Description
Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
Arm Title
Osmotic dilators + mifepristone + placebo (vit B12)
Arm Type
Active Comparator
Arm Description
Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Intervention Type
Other
Intervention Name(s)
Mifepristone
Other Intervention Name(s)
Mifeprex
Intervention Description
oral mifepristone 200 mg on Day 1.
Intervention Type
Drug
Intervention Name(s)
misoprostol
Other Intervention Name(s)
Cytotec
Intervention Description
buccal misoprostol 400 mcg on Day 2
Intervention Type
Device
Intervention Name(s)
Osmotic dilators
Other Intervention Name(s)
laminaria, Dilapan-S
Intervention Description
osmotic dilators on Day 1
Intervention Type
Other
Intervention Name(s)
placebo
Other Intervention Name(s)
vitamin C 500 mg
Intervention Description
placebo for mifepristone, on day 1
Intervention Type
Other
Intervention Name(s)
placebo
Other Intervention Name(s)
vitamin B12 500 mcg
Intervention Description
placebo for misoprostol, on day 2
Primary Outcome Measure Information:
Title
Operative Time
Description
The duration of the D&E procedure was measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D&E
Time Frame
participants were assessed for the duration of the procedure, an average of 6 minutes
Secondary Outcome Measure Information:
Title
Initial Cervical Dilation
Description
Measured at the time of procedure (immediately before the start of D&E)
Time Frame
participants were assessed during cervical dilation process, average time of 1 minute
Title
Ability to Complete the D&E on the First Attempt
Description
Assessed on day of procedure and following day. If the procedure was unable to be completed as planned and the subject had to leave the procedure room and return for another attempt either at a time later the same day or the next day.
Time Frame
participants were assessed for the duration of the procedure, an average of 6 minutes
Title
Need for Mechanical Dilation
Description
Assessed on Day of procedure. Assessed immediately after completion of D&E
Time Frame
participants were assessed for the duration of the procedure, an average of 6 minutes
Title
Ease of Mechanical Dilation
Description
Number of participants for whom, if additional mechanical dilation was required, it was difficult or very difficult. Assessed on day of procedure. Assessed after completion of D&E
Time Frame
participants were assessed for the duration of the procedure, an average of 6 minutes
Title
Complications From Procedure
Description
Patient having any complication, including hospitalizations transfusions additional unplanned procedures
Time Frame
assessed immediately after completion of D&E and at 1 week and 1 month post-procedure
Title
Chills (Any) After Day 2 Medication Administration
Description
chills (any) after Day 2 medication administration
Time Frame
assessed immediately after administration of day 2 medication
Title
Patient Satisfaction With Cervical Prep
Description
Patients who were very satisfied or satisfied with cervical preparation. Assessed on Day of procedure. Assessed after completion of D&E procedure and just prior to discharge home.
Time Frame
patients' satisfaction with cervical prep was evaluated over course of cervical prep and procedure, up to 3 days
Title
Physician Satisfaction With Cervical Preparation
Description
Participants for whom the operating physician reported being satisfied or very satisfied with the cervical preparation. Assessed on Day of procedure. Assessed after completion of D&E procedure.
Time Frame
physicians' satisfaction with cervical prep was evaluated over course of procedure, an average of 6 minutes

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18 years and older Able to give informed consent Medically eligible for outpatient second trimester pregnancy termination at the clinical site English-speaking or Spanish-speaking at sites with ability to obtain informed consent in Spanish Exclusion Criteria: Active bleeding (>1 pad/hour) or hemodynamically unstable at enrollment Signs of chorioamnionitis or clinical infection at enrollment Signs of spontaneous labor or cervical insufficiency at enrollment Spontaneous intrauterine fetal demise Patient incarcerated Allergy to mifepristone or misoprostol Chronic steroid use or adrenal insufficiency Porphyria Inflammatory bowel disease requiring treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Principal Investigator, MD, MPH
Organizational Affiliation
Planned Parenthood League of Massachusetts
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Francisco General Hospital
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Facility Name
Family Planning Associates
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60630
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Boston Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
Planned Parenthood of New York City
City
New York
State/Province
New York
ZIP/Postal Code
10012
Country
United States
Facility Name
Lovejoy Surgical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
Magee Women's Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26196084
Citation
Goldberg AB, Fortin JA, Drey EA, Dean G, Lichtenberg ES, Bednarek PH, Chen BA, Dutton C, McKetta S, Maurer R, Winikoff B, Fitzmaurice GM. Cervical Preparation Before Dilation and Evacuation Using Adjunctive Misoprostol or Mifepristone Compared With Overnight Osmotic Dilators Alone: A Randomized Controlled Trial. Obstet Gynecol. 2015 Sep;126(3):599-609. doi: 10.1097/AOG.0000000000000977.
Results Reference
derived

Learn more about this trial

Cervical Preparation Before Dilation and Evacuation

We'll reach out to this number within 24 hrs